Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-10

Clinical Trial Update: rhBNP in Type 3 Pulmonary Hypertension [Phase 4]

View source ↗

Summary

Clinical trial update for recombinant human B-type natriuretic peptide (rhBNP) in Group 3 pulmonary hypertension (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • rhBNP (recombinant human B-type natriuretic peptide)

Snippet

Sponsor: Shengjing Hospital | Conditions: Group 3 Pulmonary Hypertension | Phase 4 | Status: UNKNOWN